Trial of new compound NLX-112 to ease Dyskinesia
Parkinson’s UK and The Michael J. Fox Foundation have partnered with biopharmaceutical company Neurolixis to support a clinical trial testing the safety, tolerability, and early efficacy of NLX-112.
This is a new compound being assessed for its ability to ease dyskinesia and the severity of some non-motor symptoms of Parkinson’s.
Data from this study may allow Neurolixis to rapidly move NLX-112 into a larger Phase 3 trial, aiming to generate sufficient positive results to support the therapy’s approval.
A two-year study will involve the experimental therapy for levodopa-induced dyskinesia (LID) being given to Parkinson’s patients for a first time.
LID is a condition in which patients start having involuntary muscle movements – such as jerking or twitching – that affect their ability to perform even simple tasks. It is a common side effect of levodopa-based therapies – the main forms of treatment for Parkinson’s – among those who have been taking these medications for years.
LID is also thought to be associated with a dysregulation of serotonin-producing neurons. Recent studies have shown these neurons can take up levodopa and convert it into dopamine in an uncontrolled manner, contributing to the onset of the unintended movements that characterise dyskinesia.
Serotonin and dopamine are two types of brain chemicals (neurotransmitters) that neurons use to communicate with each other.
NLX-112 is a new compound that is able to selectively activate a sub-type of serotonin receptor called the 5-HT1A receptor, which is usually found in serotonin-producing neurons.
Once active, this receptor interferes with serotonin signalling in these nerve cells, lowering their activity. By reducing the activity of serotonin-producing neurons, NLX-112 is expected to alleviate symptoms of dyskinesia in people with Parkinson’s.
Preclinical studies have shown that NLX-112 was effective at easing dyskinesia in animal models of Parkinson’s. These findings provided the foundation for the launch of clinical trials testing NLX-112 in patients.
The clinical trails will also assess whether NLX-112 can ease some of the typical non-motor symptoms of Parkinson’s – including mood and sleep issues.
Study findings may enable NLX-112 to move into Phase 3 clinical testing, and potentially a request for its approval as a new disease treatment.
Source: Parkinson’s News Today